BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10785469)

  • 21. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
    Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
    Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
    Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
    Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
    Fagotti A; Ferrandina G; Fanfani F; Garganese G; Vizzielli G; Carone V; Salerno MG; Scambia G
    Am J Obstet Gynecol; 2008 Dec; 199(6):642.e1-6. PubMed ID: 18801470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.
    Fagotti A; Ferrandina G; Fanfani F; Ercoli A; Lorusso D; Rossi M; Scambia G
    Ann Surg Oncol; 2006 Aug; 13(8):1156-61. PubMed ID: 16791447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer.
    Qayyum A; Coakley FV; Westphalen AC; Hricak H; Okuno WT; Powell B
    Gynecol Oncol; 2005 Feb; 96(2):301-6. PubMed ID: 15661212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cytoreductive surgery for epithelial ovarian cancer.
    Hacker NF; Berek JS; Lagasse LD; Nieberg RK; Elashoff RM
    Obstet Gynecol; 1983 Apr; 61(4):413-20. PubMed ID: 6828269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.
    Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S
    Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease?
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):176-80. PubMed ID: 10926799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score.
    Brun JL; Rouzier R; Uzan S; Daraï E
    Gynecol Oncol; 2008 Sep; 110(3):354-9. PubMed ID: 18572226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
    Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
    Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.